Skip to main content

Advertisement

SpringerLink
Log in

Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer

  • Review
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Esophageal cancers have a high mortality rate and limited treatment options especially in the advanced/metastatic setting. Squamous cell carcinoma (SCC) and adenocarcinoma are two distinct types of esophageal cancer. Esophageal SCC is more common in nonindustrialized countries with risk factors including smoking, alcohol use, and achalasia. Adenocarcinoma is the predominant esophageal cancer in developed nations, and risk factors include chronic gastroesophageal reflux disease, obesity, and smoking. Chemotherapy has been the mainstay of therapy for decades until immunotherapy made its debut in the past few years. Immune checkpoint inhibitors have been tested in many studies now and are becoming an essential component of esophageal cancer treatment. Monoclonal antibodies that selectively inhibit programmed cell death-1 (PD-1) activity such as pembrolizumab and nivolumab, have become standard of care in the treatment of esophageal cancer. Several other anti-PD-1 antibodies like camrelizumab, toripalimab, sintilimab, trislelizumab are under investigation in different stages of clinical trials. Here we provide a comprehensive review of extant literature as well as ongoing trials with various combinations of chemotherapy or other targeted therapy with a focus on different histological subgroups of esophageal cancer and in different clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

    Article  PubMed  Google Scholar 

  2. Uhlenhopp DJ et al (2020) Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 13(6):1010–1021

    Article  PubMed  Google Scholar 

  3. Ajani JA et al (2017) Gastric adenocarcinoma. Nat Rev Dis Primers 3:17036

    Article  PubMed  Google Scholar 

  4. Cancer Genome Atlas Research et al (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541(7636):169–175

    Article  Google Scholar 

  5. Boussiotis VA, Chatterjee P, Li L (2014) Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J 20(4):265–271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. He W et al (2017) CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res 77(22):6375–6388

    Article  CAS  PubMed  Google Scholar 

  7. Kollmann D et al (2018) PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology 7(6):e1435226

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kulangara K et al (2017) Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx. J Clin Oncol 35:14589–14589

    Article  Google Scholar 

  9. Pimentel-Nunes P et al (2022) Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of gastrointestinal endoscopy (ESGE) guideline-update 2022. Endoscopy 54(6):591–622

    Article  PubMed  Google Scholar 

  10. van Hagen P et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084

    Article  PubMed  Google Scholar 

  11. Al-Batran SE et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel vs fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957

    Article  PubMed  Google Scholar 

  12. Zhu M et al (2022) Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction. Clin Cancer Res 28(14):3021–3031

    Article  CAS  PubMed  Google Scholar 

  13. van den Ende T et al (2021) Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin Cancer Res 27(12):3351–3359

    Article  PubMed  Google Scholar 

  14. Gao L et al (2022) Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2). J Gastrointest Oncol 13(2):478–487

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zhang Z et al (2021) Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1). Ann Transl Med 9(21):1623

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Liu J et al (2022) Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer 151(1):128–137

    Article  CAS  PubMed  Google Scholar 

  17. Kelly RJ et al (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384(13):1191–1203

    Article  CAS  PubMed  Google Scholar 

  18. Wagner AD et al (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 8:CD004064

    PubMed  Google Scholar 

  19. Sun JM et al (2021) Pembrolizumab plus chemotherapy vs chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398(10302):759–771

    Article  CAS  PubMed  Google Scholar 

  20. Doki Y et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386(5):449–462

    Article  CAS  PubMed  Google Scholar 

  21. Lu Z et al (2022) Sintilimab vs placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 377:e068714

    Article  PubMed  PubMed Central  Google Scholar 

  22. Wang ZX et al (2022) Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 40(3):277–288

    Article  CAS  PubMed  Google Scholar 

  23. Luo H et al (2021) Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326(10):916–925

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Janjigian YY et al (2021) First-line nivolumab plus chemotherapy vs chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27–40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Shah MA et al (2019) Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol 5(4):546–550

    Article  PubMed  Google Scholar 

  26. Cao Y et al (2022) Pembrolizumab vs chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia. ESMO Open 7(1):100341

    Article  CAS  PubMed  Google Scholar 

  27. Kato K et al (2019) Nivolumab vs chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(11):1506–1517

    Article  CAS  PubMed  Google Scholar 

  28. Shen L et al (2022) Tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol 40(26):2101926

    Article  Google Scholar 

  29. Huang J et al (2020) Camrelizumab vs investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 21(6):832–842

    Article  CAS  PubMed  Google Scholar 

  30. Xu J et al (2022) Clinical and biomarker analyses of sintilimab vs chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun 13(1):857

    Article  PubMed  PubMed Central  Google Scholar 

  31. Fuchs CS et al (2022) Pembrolizumab vs paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer 25(1):197–206

    Article  CAS  PubMed  Google Scholar 

  32. Kang YK et al (2022) Nivolumab plus chemotherapy vs placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(2):234–247

    Article  CAS  PubMed  Google Scholar 

  33. Yoon HH et al (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 30(32):3932–3938

    Article  PubMed  PubMed Central  Google Scholar 

  34. Chung HC et al (2021) First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 17(5):491–501

    Article  CAS  PubMed  Google Scholar 

  35. Stein A et al (2022) Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial. JAMA Oncol 8(8):1150–1158

    PubMed  PubMed Central  Google Scholar 

  36. Bang YJ et al (2010) Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

    Article  CAS  PubMed  Google Scholar 

  37. Zhang B et al (2020) Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond) 40(12):711–720

    Article  PubMed  Google Scholar 

  38. Meng X et al (2022) Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):245–253

    Article  PubMed  Google Scholar 

  39. Leone AG et al (2022) Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score. ESMO Open 7(1):100380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yoon HH et al (2022) Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol 8(10):1456–1465

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, University of Cincinnati Medical Center, Cincinnati, USA

    Ningjing Li & Davendra Sohal

Authors
  1. Ningjing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davendra Sohal
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Davendra Sohal.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, N., Sohal, D. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer. Cancer Immunol Immunother 72, 3939–3952 (2023). https://doi.org/10.1007/s00262-023-03566-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-023-03566-5

Keywords

Search

Navigation